宽容性树突细胞和M2巨细胞极化诱导混合纳米颗粒可缓解小鼠喘
Eun-Koung An1, Wei Zhang2, Hae-Bin Park1
1Department of Microbiology, Brain Korea 21 Project, University of Ulsan College of Medicine, ASAN Medical Center, Seoul 05505, South Korea.
ACS nano
|June 24, 2025
概括
这项研究引入了用于喘治疗的混合纳米粒子 (DM-HNPs). 这些纳米颗粒有效抑制免疫细胞激活,促进调节性T细胞生成,为喘患者提供潜在的治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘是一种具有潜在致命后果的慢性呼吸道炎症疾病.
- 目前的治疗方法侧重于控制症状,突出显示出需要新的治疗策略.
- 药物输送系统为喘中的向免疫调节提供了有希望的途径.
研究的目的:
- 开发和评估一种用于喘治疗的新型混合纳米粒子系统.
- 为了研究德克萨米他和单脂A (MPLA) 装载纳米粒子的免疫调节作用.
- 评估这些纳米粒子在抑制喘发病和进展方面的潜力.
主要方法:
- 混合纳米颗粒 (DM-HNPs) 是通过将德克萨米他 (Dex) 装载到聚乳酸-联合甘油酸上并用单酸脂A (MPLA) 进行封装而制成的.
- 给小鼠使用DM-HNP来评估它们对树突细胞 (DC) 和巨细胞的向.
- 评估了免疫细胞激活,细胞因子生产 (IL-10) 和调节性T细胞生成.
主要成果:
- 在体内,DM-HNP有效地向并抑制DC和巨细胞的激活.
- 在免疫细胞中,DM-HNP显著增加了互白素-10 (IL-10) 的产生.
- 这些纳米颗粒促进了耐受性DC和M2巨细胞分化,以及调节性T细胞诱导.
结论:
- 通过调节免疫反应,DM-HNP在抑制喘发病和进展方面表现出有效性.
- 开发的混合纳米颗粒显示出作为喘治疗治疗剂的潜力.
- 通过纳米颗粒提供甲和MPLA的向输送为管理喘等免疫媒介疾病提供了一个有希望的策略.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
484
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
484
01:20Asthma: Pathogenesis and Management
618
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
618
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
502
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
502